| 0.5339 0.013 (2.48%) | 04-25 09:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.68 | 1-year : | 0.89 |
| Resists | First : | 0.58 | Second : | 0.76 |
| Pivot price | 0.56  |
|||
| Supports | First : | 0.3 | Second : | 0.25 |
| MAs | MA(5) : | 0.47  |
MA(20) : | 0.59 |
| MA(100) : | 0.74 |
MA(250) : | 1.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 36.3 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 2.07 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PPBT ] has closed above bottom band by 37.2%. Bollinger Bands are 75.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.6 |
| Low: | 0.47 - 0.47 | 0.47 - 0.47 |
| Close: | 0.51 - 0.51 | 0.51 - 0.52 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Thu, 25 Apr 2024
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster ... - GlobeNewswire
Thu, 28 Mar 2024
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 - GlobeNewswire
Thu, 28 Mar 2024
Purple Biotech's NT219 Shows Promising Cancer Fight - TipRanks.com - TipRanks
Wed, 13 Mar 2024
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Thu, 07 Mar 2024
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate - Simply Wall St
Tue, 05 Mar 2024
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 236 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 222 (K) |
| Shares Short P.Month | 296 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.2 % |
| Return on Equity (ttm) | -49.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 0 |
| Price to Book value | 3.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|